Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Urology,Oncology
Reference20 articles.
1. Gravas S, Cornu JN, Gacci M, CC Gratzke, Herrmann TRW, Mamoulakis C, et al. EAU guidelines—management of non-neurogenic male LUTS. 2019:Chapter 5.2.2;18.
2. Iczkowski KA, Qiu J, Qian J, Somerville MC, Rittmaster RS, Andriole GL, et al. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. Urology. 2005;65:76–82. https://doi.org/10.1016/j.urology.2004.08.042.
3. Roznovanu SL, Rădulescu D, Novac C, Stolnicu S. The morphologic changes induced by hormone and radiation therapy on prostate carcinoma. Rev Med Chir Soc Med Nat Iasi. 2005;109:337–42.
4. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N. Engl J Med. 2010;362:1192–202.
5. Fleshner NE, Lucia MS, Egerdie B, Aaron L, Eure G, Nandy I, et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double blind, placebo-controlled trial. Lancet. 2012;379:1103–11.